REFERENCES
1. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res 2017;121:677-94.
2. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459-544.
3. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018;392:2052-90.
4. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-7.
6. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013;9:617-70.
7. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-8.
8. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 2007;65:S140-6.
9. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007;13:3-10.
10. Reyes L, Herrera D, Kozarov E, Roldá S, Progulske-Fox A. Periodontal bacterial invasion and infection: contribution to atherosclerotic pathology. J Periodontol 2013;84:S30-50.
11. Pietiäinen M, Liljestrand JM, Kopra E, Pussinen PJ. Mediators between oral dysbiosis and cardiovascular diseases. Eur J Oral Sci 2018;126:26-36.
12. Carrizales-Sepúlveda EF, Ordaz-Farías A, Vera-Pineda R, Flores-Ramírez R. Periodontal disease, systemic inflammation and the risk of cardiovascular disease. Heart Lung Circ 2018;27:1327-34.
13. Mesa F, Magan-Fernandez A, Castellino G, Chianetta R, Nibali L, et al. Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives. Biochim Biophys Acta Mol Basis Dis 2019;1865:476-84.
14. Kozarov E, Progulske-Fox A. Pocket guide to bacterial infections. In: Balamurugan K, Udayakumar P, editors. Boca Raton FL: CRC Press; 2019. p. 398.
15. Bui FQ, Almeida-da-Silva CLC, Huynh B, Trinh A, Liu J, et al. Association between periodontal pathogens and systemic disease. Biomed J 2019;42:27-35.
16. Liccardo D, Cannavo A, Spagnuolo G, Ferrara N, Cittadini A, et al. Periodontal disease: a risk factor for diabetes and cardiovascular disease. Int J Mol Sci 2019;20:1414.
17. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al; CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013;45:25-33.
18. Björkegren JLM, Kovacic JC, Dudley JT, Schadt EE. Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol 2015;65:830-45.
19. JPatron J, Serra-Cayuela A, Han B, Li C, Wishart DS. Assessing the performance of genome-wide association studies for predicting disease risk. PLoS One 2019;14:e0220215.
21. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
22. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
23. Lowe GD. The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol 2001;6:1-8.
24. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004;116:9S-16S.
25. Elkind MS. Infectious burden: a new risk factor and treatment target for atherosclerosis. Infect Disord Drug Targets 2010;10:84-90.
26. Elkind MS, Luna JM, Moon YP, Boden-Albala B, Liu KM, et al. Infectious burden and carotid plaque thickness: the Northern Manhattan Study. Stroke 2010;41:e117-22.
27. Elkind MSV, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, et al. Infectious burden and risk of stroke: the Northern Manhattan Study. Arch Neurol 2010;67:33-8.
28. Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, et al. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology 2013;80:1209-15.
29. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, et al; Oral Infections and Vascular Disease Epidemiology Study (INVEST). Relationship between periodontal disease, tooth loss, and carotid artery plaque: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke 2003;34:2120-5.
30. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005;111:576-82.
31. Engebretson SP, Lamster IB, Elkind MS, Rundek T, Serman NJ, et al. Radiographic measures of chronic periodontitis and carotid artery plaque. Stroke 2005;36:561-6.
32. Desvarieux M, Demmer RT, Jacobs DR Jr, Rundek T, Boden-Albala B, et al. Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST). J Hypertens 2010;28:1413-21.
33. Boillot A, Demmer RT, Mallat Z, Sacco RL, Jacobs DR, et al. Periodontal microbiota and phospholipases: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Atherosclerosis 2015;242:418-23.
34. Elter JR, Champagne CM, Offenbacher S, Beck JD. Relationship of periodontal disease and tooth loss to prevalence of coronary heart disease. J Periodontol 2004;75:782-90.
35. Rydén L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, et al. Periodontitis increases the risk of a first myocardial infarction: a report from the PAROKRANK Study. Circulation 2016;133:576-83.
36. Górski B, Nargiełło E, Grabowska E, Opolski G, Górska R. The association between dental status and risk of acute myocardial infarction among poles: case-control study. Adv Clin Exp Med 2016;25:861-70.
37. Nordendahl E, Gustafsson A, Norhammar A, Näsman P, Rydén L, et al; PAROKRANK Steering Committee. Severe periodontitis is associated with myocardial infarction in females. J Dent Res 2018;97:1114-21.
38. Pasqualini D, Bergandi L, Palumbo L, Borraccino A, Dambra V, et al. Association among oral health, apical periodontitis, CD14 polymorphisms, and coronary heart disease in middle-aged adults. J Endod 2012;38:1570-7.
39. Morita T, Yamazaki Y, Fujiharu C, Ishii T, Seto M, et al. Association between the duration of periodontitis and increased cardiometabolic risk factors: a 9-year cohort study. Metab Syndr Relat Disord 2016;14:475-82.
40. Jönsson D, Orho-Melander M, Demmer RT, Engström G, Melander O, et al. Periodontal disease is associated with carotid plaque area: the Malmö Offspring Dental Study (MODS). J Intern Med 2020;287:301-9.
41. Cotti E, Dessì C, Piras A, Mercuro G. Can a chronic dental infection be considered a cause of cardiovascular disease? A review of the literature. Int J Cardiol 2011;148:4-10.
42. Cotti E, Mercuro G. Apical periodontitis and cardiovascular diseases: previous findings and ongoing research. Int Endod J 2015;48:926-32.
43. Chauhan N, Mittal S, Tewari S, Sen J, Laller K. Association of apical periodontitis with cardiovascular disease via noninvasive assessment of endothelial function and subclinical atherosclerosis. J Endod 2019;45:681-90.
44. Pussinen PJ, Mattila K. Periodontal infections and atherosclerosis: mere associations? Curr Opin Lipidol 2004;15:583-8.
45. Amar S, Wu SC, Madan M. Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications. J Immunol 2009;182:1584-92.
46. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation 2009;119:3133-41.
47. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. J Am Dent Assoc 2002;133:14S-22.
48. Beck JD, Eke P, Heiss G, Madianos P, Couper D, et al. Periodontal disease and coronary heart disease: a reappraisal of the exposure. Circulation 2005;112:19-24.
49. Beck JD, Moss KL, Morelli T, Offenbacher S. Periodontal profile class is associated with prevalent diabetes, coronary heart disease, stroke, and systemic markers of C-reactive protein and interleukin-6. J Periodontol 2018;89:157-65.
50. Pussinen PJ, Jousilahti P, Alfthan G, Palosuo T, Asikainen S, et al. Antibodies to periodontal pathogens are associated with coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23:1250-4.
51. Pussinen PJ, Alfthan G, Rissanen H, Reunanen A, Asikainen S, et al. Antibodies to periodontal pathogens and stroke risk. Stroke 2004;35:2020-3.
52. Pussinen PJ, Alfthan G, Jousilahti P, Paju S, Tuomilehto J. Systemic exposure to Porphyromonas gingivalis predicts incident stroke. Atherosclerosis 2007;193:222-8.
53. Pussinen PJ, Jauhiainen M, Vilkuna-Rautiainen T, Sundvall J, Vesanen M, et al. Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J Lipid Res 2004;45:139-47.
54. Kim HJ, Cha GS, Kim HJ, Kwon EY, Lee JY, et al. Porphyromonas gingivalis accelerates atherosclerosis through oxidation of high-density lipoprotein. J Periodontal Implant Sci 2018;48:60-8.
55. Pussinen PJ, Könönen E, Paju S, Hyvärinen K, Gursoy UK, et al. Periodontal pathogen carriage, rather than periodontitis, determines the serum antibody levels. J Clin Periodontol 2011;38:405-11.
56. Miyashita H, Honda T, Maekawa T, Takahashi N, Aoki Y, et al. Relationship between serum antibody titres to Porphyromonas gingivalis and hs-CRP levels as inflammatory markers of periodontitis. Arch Oral Biol 2012;57:820-9.
57. Yamazaki K, Honda T, Domon H, Okui T, Kajita K, et al. Relationship of periodontal infection to serum antibody levels to periodontopathic bacteria and inflammatory markers in periodontitis patients with coronary heart disease. Clin Exp Immunol 2007;149:445-52.
58. Sanchez-Torres D, Gutierrez-Bejarano D, Hurtado-Roca Y, Guallar-Castillon P, Muntner P, et al. Non-linear association of periodontal pathogen antibodies with mortality. Int J Cardiol 2015;187:628-36.
59. Pussinen PJ, Paju S, Koponen J, Viikari JSA, Taittonen L, et al. Association of childhood oral infections with cardiovascular risk factors and subclinical atherosclerosis in adulthood. JAMA Netw Open 2019;2:e192523.
60. Akhi R, Wang C, Nissinen AE, Kankaanpää J, Bloigu R, et al. Salivary IgA to MAA-LDL and oral pathogens are linked to coronary disease. J Dent Res 2019;98:296-303.
61. Liljestrand JM, Paju S, Pietiäinen M, Buhlin K, Persson GR, et al. Immunologic burden links periodontitis to acute coronary syndrome. Atherosclerosis 2018;268:177-84.
62. Silver JG, Martin AW, McBride BC. Experimental transient bacteraemias in human subjects with varying degrees of plaque accumulation and gingival inflammation. J Clin Periodontol 1977;4:92-9.
63. Lockhart PB. An analysis of bacteremias during dental extractions. A double-blind, placebo-controlled study of chlorhexidine. Arch Intern Med 1996;156:513-20.
64. Lockhart PB, Brennan MT, Kent ML, Norton HJ, Weinrib DA. Impact of amoxicillin prophylaxis on the incidence, nature, and duration of bacteremia in children after intubation and dental procedures. Circulation 2004;109:2878-84.
65. Tomás I, Diz P, Tobías A, Scully C, Donos N. Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. J Clin Periodontol 2012;39:213-28.
66. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000;71:1554-60.
67. Kozarov E, Sweier D, Shelburne C, Progulske-Fox A, Lopatin D. Detection of bacterial DNA in atheromatous plaques by quantitative PCR. Microbes Infect 2006;8:687-93.
68. Toyofuku T, Inoue Y, Kurihara N, Kudo T, Jibiki M, et al. Differential detection rate of periodontopathic bacteria in atherosclerosis. Surg Today 2011;41:1395-400.
69. Pyysalo MJ, Pyysalo LM, Pessi T, Karhunen PJ, Öhman JE. The connection between ruptured cerebral aneurysms and odontogenic bacteria. J Neurol Neurosurg Psychiatry 2013;84:1214-8.
70. Pyysalo MJ, Pyysalo LM, Pessi T, Karhunen PJ, Lehtimäki T, et al. Bacterial DNA findings in ruptured and unruptured intracranial aneurysms. Acta Odontol Scand 2016;74:315-20.
71. Gaetti-Jardim E Jr, Marcelino SL, Feitosa AC, Romito GA, Avila-Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. J Med Microbiol 2009;58:1568-75.
72. Calandrini CA, Ribeiro AC, Gonnelli AC, Ota-Tsuzuki C, Rangel LP, et al. Microbial composition of atherosclerotic plaques. Oral Dis 2014;20:e128-34.
73. Szulc M, Kustrzycki W, Janczak D, Michalowska D, Baczynska D, et al. Presence of periodontopathic bacteria DNA in atheromatous plaques from coronary and carotid arteries. Biomed Res Int 2015;2015:825397.
74. Kozarov EV, Dorn BR, Shelburne CE, Dunn WA Jr, Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005;25:e17-8.
75. Rafferty B, Jönsson D, Kalachikov S, Demmer RT, Nowygrod R, et al. Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions. J Intern Med 2011;270:273-80.
76. Rafferty B, Dolgilevich S, Kalachikov S, Morozova I, Ju J, et al. Cultivation of Enterobacter hormaechei from human atherosclerotic tissue. J Atheroscler Thromb 2011;18:72-81.
77. Cross KL, Campbell JH, Balachandran M, Campbell AG, Cooper SJ, et al. Targeted isolation and cultivation of uncultivated bacteria by reverse genomics. Nat Biotechnol 2019;37:1314-21.
78. Weise H, Naros A, Weise C, Reinert S, Hoefert S. Severe odontogenic infections with septic progress - a constant and increasing challenge: a retrospective analysis. BMC Oral Health 2019;19:173.
79. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019;5:eaau3333.
80. Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2003;23:1405-11.
81. Ezzahiri R, Stassen FR, Kurvers HA, van Pul MM, Kitslaar PJ, et al. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc Surg 2003;26:88-95.
82. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 2011;108:4592-8.
83. Roth GA, Moser B, Huang SJ, Brandt JS, Huang Y, et al. Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. J Thromb Haemost 2006;4:2256-61.
84. Gibson FC, Hong C, Chou HH, Yumoto H, Chen J, et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:2801-6.
85. Liberto MC, Matera G, Lamberti AG, Barreca GS, Quirino A, et al. In vitro Bartonella quintana infection modulates the programmed cell death and inflammatory reaction of endothelial cells. Diagn Microbiol Infect Dis 2003;45:107-15.
86. Potempa J, Banbula A, Travis J. Role of bacterial proteinases in matrix destruction and modulation of host responses. Periodontol 2000 2000;24:153-92.
87. Potempa J, Sroka A, Imamura T, Travis J. Gingipains, the major cysteine proteinases and virulence factors of Porphyromonas gingivalis: structure, function and assembly of multidomain protein complexes. Curr Protein Pept Sci 2003;4:397-407.
88. Travis J, Banbula A, Potempa J. The role of bacterial and host proteinases in periodontal disease. Adv Exp Med Biol 2000;477:455-65.
89. Johansson A, Kalfas S. Characterization of the proteinase-dependent cytotoxicity of Porphyromonas gingivalis. Eur J Oral Sci 1998;106:863-71.
90. Chen T, Nakayama K, Belliveau L, Duncan MJ. Porphyromonas gingivalis gingipains and adhesion to epithelial cells. Infect Immun 2001;69:3048-56.
91. Roth GA, Ankersmit HJ, Brown VB, Papapanou PN, Schmidt AM, et al. Porphyromonas gingivalis infection and cell death in human aortic endothelial cells. FEMS Microbiol Lett 2007;272:106-13.
92. Hirasawa M, Kurita-Ochiai T. Porphyromonas gingivalis induces apoptosis and autophagy via ER stress in human umbilical vein endothelial cells. Mediators Inflamm 2018;2018:1967506.
93. Pham K, Feik D, Hammond BF, Rams TE, Whitaker EJ. Aggregation of human platelets by gingipain-R from Porphyromonas gingivalis cells and membrane vesicles. Platelets 2002;13:21-30.
94. Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, et al. Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. Blood 2001;97:3790-7.
95. Arvanitidis E, Bizzarro S, Alvarez Rodriguez E, Loos BG, Nicu EA. Reduced platelet hyper-reactivity and platelet-leukocyte aggregation after periodontal therapy. Thromb J 2017;15:5.
96. Klarström Engström K, Khalaf H, Kälvegren H, Bengtsson T. The role of Porphyromonas gingivalis gingipains in platelet activation and innate immune modulation. Mol Oral Microbiol 2015;30:62-73.
97. Lönn J, Ljunggren S, Klarström-Engström K, Demirel I, Bengtsson T, et al. Lipoprotein modifications by gingipains of Porphyromonas gingivalis. J Periodontal Res 2018;53:403-13.
98. Joo JY, Cha GS, Chung J, Lee JY, Kim SJ, et al. Peptide 19 of porphyromonas gingivalis heat shock protein is a potent inducer of low-density lipoprotein oxidation. J Periodontol 2017;88:e58-e64.
99. Wallet SM, Puri V, Gibson FC. Linkage of infection to adverse systemic complications: periodontal disease, toll-like receptors, and other pattern recognition systems. Vaccines (Basel) 2018;6:21.
100. Hernández-Ríos P, Pussinen PJ, Vernal R, Hernández M. Oxidative stress in the local and systemic events of apical periodontitis. Front Physiol 2017;8:869.
101. Sessa R, Pietro MD, Filardo S, Turriziani O. Infectious burden and atherosclerosis: a clinical issue. World J Clin Cases 2014;2:240-9.
102. He F, Zuo L. Redox roles of reactive oxygen species in cardiovascular diseases. Int J Mol Sci 2015;16:27770-80.
103. Di Pietro M, Filardo S, Falasca F, Turriziani O, Sessa R. Infectious agents in atherosclerotic cardiovascular diseases through oxidative stress. Int J Mol Sci 2017;18:2459.
104. Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res 2017;120:713-35.
105. Li L, Michel R, Cohen J, Decarlo A, Kozarov E. Intracellular survival and vascular cell-to-cell transmission of Porphyromonas gingivalis. BMC Microbiol 2008;8:26.
106. Azenabor AA, Yang S, Job G, Adedokun OO. Elicitation of reactive oxygen species in Chlamydia pneumoniae-stimulated macrophages: a Ca2+-dependent process involving simultaneous activation of NADPH oxidase and cytochrome oxidase genes. Med Microbiol Immunol 2005;194:91-103.
107. Di Pietro M, Filardo S, De Santis F, Sessa R. Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview. Int J Mol Sci 2013;14:15105-20.
108. Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T, Ando T. Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis. Pathog Dis 2015;73:ftv011.
109. Li XY, Wang C, Xiang XR, Chen FC, Yang CM, et al. Porphyromonas gingivalis lipopolysaccharide increases lipid accumulation by affecting CD36 and ATP-binding cassette transporter A1 in macrophages. Oncol Rep 2013;30:1329-36.
110. Pollreisz A, Huang Y, Roth GA, Cheng B, Kebschull M, et al. Enhanced monocyte migration and pro-inflammatory cytokine production by Porphyromonas gingivalis infection. J Periodontal Res 2010;45:239-45.
111. Sheets SM, Potempa J, Travis J, Casiano CA, Fletcher HM. Gingipains from Porphyromonas gingivalis W83 induce cell adhesion molecule cleavage and apoptosis in endothelial cells. Infect Immun 2005;73:1543-52.
112. Bugueno IM, Khelif Y, Seelam N, Morand DN, Tenenbaum H, et al. Porphyromonas gingivalis differentially modulates cell death profile in Ox-LDL and TNF-α pre-treated endothelial cells. PLoS One 2016;11:e0154590.
113. Shiheido Y, Maejima Y, Suzuki JI, Aoyama N, Kaneko M, et al. Porphyromonas gingivalis, a periodontal pathogen, enhances myocardial vulnerability, thereby promoting post-infarct cardiac rupture. J Mol Cell Cardiol 2016;99:123-37.
114. Amberger A, Maczek C, Jürgens G, Michaelis D, Schett G, et al. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 1997;2:94-103.
115. Takei A, Huang Y, Lopes-Virella MF. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis 2001;154:79-86.
116. Malekmohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants and atherosclerosis: mechanistic aspects. Biomolecules 2019;9:301.
117. Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med 2010;14:70-8.
118. Li L, Messas E, Batista EL Jr, Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002;105:861-7.
119. Jain A, Batista EL Jr, Serhan C, Stahl GL, Van Dyke TE. Role for periodontitis in the progression of lipid deposition in an animal model. Infect Immun 2003;71:6012-8.
120. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-96.
121. Hardardóttir I, Grunfeld C, Feingold KR. Effects of endotoxin on lipid metabolism. Biochem Soc Trans 1995;23:1013-8.
122. Pirillo A, Catapano AL, Norata GD. HDL in infectious diseases and sepsis. Handb Exp Pharmacol 2015;224:483-508.
123. Lassenius MI, Pietiläinen KH, Kaartinen K, Pussinen PJ, Syrjänen J, et al; FinnDiane Study Group. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011;34:1809-15.
124. Feingold KR, Grunfeld C. in Endotext KR, Feingold et al., Eds. MDText.com, Inc., South Dartmouth (MA); 2000. Available from https://www.ncbi.nlm.nih.gov/books/NBK326741/ [Last accessed on 27 Feb 2020].
125. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, et al. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 1999;40:245-52.
126. Moretti E, Gonnelli S, Campagna M, Nuti R, Collodel G, et al. Influence of Helicobacter pylori infection on metabolic parameters and body composition of dyslipidemic patients. Intern Emerg Med 2014;9:767-72.
127. Saxlin T, Suominen-Taipale L, Kattainen A, Marniemi J, Knuuttila M, et al. Association between serum lipid levels and periodontal infection. J Clin Periodontol 2008;35:1040-7.
128. Korhonen S, Saxlin T, Suominen L, Jula A, Knuuttila M, et al. Serum cholesterol ratios and periodontal infection: results of the Health 2000 Survey. J Clin Periodontol 2011;38:787-94.
129. Nishimura F, Taniguchi A, Yamaguchi-Morimoto M, Soga Y, Iwamoto Y, et al. Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression. Horm Metab Res 2006;38:530-5.
130. Nepomuceno R, Pigossi SC, Finoti LS, Orrico SRP, Cirelli JA, et al. Serum lipid levels in patients with periodontal disease: a meta-analysis and meta-regression. J Clin Periodontol 2017;44:1192-207.
131. Van Dyke TE. The management of inflammation in periodontal disease. J Periodontol 2008;79:1601-8.
132. Van Dyke TE, Kornman KS. Inflammation and factors that may regulate inflammatory response. J Periodontol 2008;79:1503-7.
133. Hasturk H, Kantarci A, Van Dyke TE. Paradigm shift in the pharmacological management of periodontal diseases. Front Oral Biol 2012;15:160-76.
134. Grover V, Malhotra R, Kapoor A, Singh J, Sachdeva S. Proresolution mediators and receptors: novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation. Infect Disord Drug Targets 2013;13:75-84.
135. Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol 2015;35:1123-33.
136. Hamilton JA, Hasturk H, Kantarci A, Serhan CN, Van Dyke T. Atherosclerosis, periodontal disease, and treatment with resolvins. Curr Atheroscler Rep 2017;19:57.
137. Elter JR, Hinderliter AL, Offenbacher S, Beck JD, Caughey M, et al. The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am Heart J 2006;151:47.
138. Shimada Y, Komatsu Y, Ikezawa-Suzuki I, Tai H, Sugita N, et al. The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol 2010;81:1118-23.
139. Desvarieux M, Demmer RT, Jacobs DR, Papapanou PN, Sacco RL, et al. Changes in clinical and microbiological periodontal profiles relate to progression of carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology study. J Am Heart Assoc 2013;2:e000254.
140. D’Aiuto F, Nibali L, Parkar M, Patel K, Suvan J, et al. Oxidative stress, systemic inflammation, and severe periodontitis. J Dent Res 2010;89:1241-6.
141. D’Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Clin Periodontol 2013;40:S85-105.
142. Inchingolo F, Marrelli M, Annibali S, Cristalli MP, Dipalma G, et al. Influence of endodontic treatment on systemic oxidative stress. Int J Med Sci 2013;11:1-6.
143. Saffi MAL, Rabelo-Silva ER, Polanczyk CA, Furtado MV, Montenegro MM, et al. Periodontal therapy and endothelial function in coronary artery disease: a randomized controlled trial. Oral Dis 2018;24:1349-57.
144. Wang Y, Andrukhov O, Rausch-Fan X. Oxidative stress and antioxidant system in periodontitis. Front Physiol 2017;8:910.
145. Scannapieco FA, Dasanayake AP, Chhun N. Does periodontal therapy reduce the risk for systemic diseases?. Dent Clin North Am 2010;54:163-81.
146. Falcao A, Bullón P. A review of the influence of periodontal treatment in systemic diseases. Periodontol 2000 2019;79:117-28.
147. Orlandi M, Suvan J, Petrie A, Donos N, Masi S, et al. Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis. Atherosclerosis 2014;236:39-46.
148. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, et al. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292-5.
149. Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. Future Cardiol 2012;8:123-38.
150. Libby P. Fanning the flames: inflammation in cardiovascular diseases. Cardiovasc Res 2015;107:307-9.
151. Joensen JB, Juul S, Henneberg E, Thomsen G, Ostergaard L, et al. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 2008;196:937-42.
152. Vainas T, Stassen FR, Schurink GW, Tordoir JH, Welten RJ, et al. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2005;29:403-11.
153. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207.e15.
154. Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc 2013;124:174-90.
155. Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013;15:295.
156. Moreira DM, Lueneberg ME, da Silva RL, Fattah T, Mascia Gottschall CA. Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation. Cardiology 2013;126:167-70.
157. O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15.
158. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis 2000;181:S572-8.
159. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
160. Amar S, Engelke M. Periodontal innate immune mechanisms relevant to atherosclerosis. Mol Oral Microbiol 2015;30:171-85.
161. Kesavalu L, Lucas AR, Verma RK, Liu L, Dai E, et al. Increased atherogenesis during Streptococcus mutans infection in ApoE-null mice. J Dent Res 2012;91:255-60.
162. Kozarov E, Huber K, Wojta J. Infection-associated biomarkers of inflammation in atherosclerosis. Curr Pharm Des 2015;21:1776-82.
163. Kramer CD, Simas AM, He X, Ingalls RR, Weinberg EO, et al. Distinct roles for dietary lipids and Porphyromonas gingivalis infection on atherosclerosis progression and the gut microbiota. Anaerobe 2017;45:19-30.
164. Anderson JL. Infection, antibiotics, and atherothrombosis--end of the road or new beginnings? N Engl J Med 2005;352:1706-9.
165. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001;103:351-6.
166. Deshpande RG, Khan M, Genco CA. Invasion strategies of the oral pathogen porphyromonas gingivalis: implications for cardiovascular disease. Invasion Metastasis ;18:57-69.
167. Dorn BR, Dunn WA Jr, Progulske-Fox A. Invasion of human coronary artery cells by periodontal pathogens. Infect Immun 1999;67:5792-8.
168. Lamont RJ, Chan A, Belton CM, Izutsu KT, Vasel D, et al. Porphyromonas gingivalis invasion of gingival epithelial cells. Infect Immun 1995;63:3878-85.
169. Progulske-Fox A, Kozarov E, Dorn B, Dunn W Jr, Burks J, et al. Porphyromonas gingivalis virulence factors and invasion of cells of the cardiovascular system. J Periodontal Res 1999;34:393-9.
170. Wunsch CM, Lewis JP. Porphyromonas gingivalis as a Model Organism for Assessing Interaction of Anaerobic Bacteria with Host Cells. J Vis Exp 2015:e53408.
171. Griffen AL, Becker MR, Lyons SR, Moeschberger ML, Leys EJ. Prevalence of Porphyromonas gingivalis and periodontal health status. J Clin Microbiol 1998;36:3239-42.
172. Rudney JD, Chen R. The vital status of human buccal epithelial cells and the bacteria associated with them. Arch Oral Biol 2006;51:291-8.
173. Donley TG. Time to put periodontal disease on the list of chronic inflammatory diseases contributing to premature atherosclerosis. CMAJ 2019;191:E52.
